Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension

NCT01152567 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01152567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01152567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 30, 2010
Completion date
November 30, 2010
Enrollment
50,000 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, hypertension